SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject12/2/2002 2:51:27 PM
From: nigel bates   of 631
 
Serono / TBP-1

LONDON, Dec 2 (Reuters) - Swiss-based Serono SA (SEOZ.VX) said on Monday it was on track to carve out a new business in the treatment of psoriasis and planned to start final clinical trials of an experimental treatment, TBP-1, in mid-2003.
"This is a new opportunity for Serono to add another therapeutic area into our portfolio," Deputy CEO Jacques Theurillat told an analysts' meeting in London.
Europe's biggest biotechnology company is already a major player in multiple sclerosis, fertility treatment, and growth and metabolic disorders. Theurillat said Serono aimed to broaden this base by adding two new "franchises" in the coming years.
The firm has adopted a twin-track approach to psoriasis, developing TBP-1 from its in-house research while at the same time licensing European rights to another drug, called Raptiva, from U.S. biotech group Genentech Inc (NYSE:DNA - News).
The company aims to file for regulatory approval to sell Raptiva in Europe in the first quarter of 2003 and the product is expected to go on sale for the treatment of the inflammatory skin condition in 2004.
The decision to advance TBP-1 into final Phase III studies next year follows encouraging results from key Phase II trials in psoriasis and psoriatic arthritis, details of which were unveiled at the meeting in London...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News